{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:44:01Z","timestamp":1786725841342,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women. PCOS comprises a broad spectrum of anomalies, including hyperandrogenism, chronic anovulation, obesity, and infertility. Insulin resistance and its compensatory hyperinsulinemia play a key role in the pathogenicity of PCOS. This study compares the effects of 2 types of insulin sensitizer drugs, metformin and pioglitazone, on clinical, metabolic, and endocrine characteristics of women with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this randomized clinical trial, 56 women with PCOS (ages 20\u201349 years) were treated orally with either metformin (500 mg 3 times daily) or pioglitazone (30 mg daily) for 3 months. Clinical (body weight, blood pressure [BP], and body mass index) and laboratory indices (fasting blood sugar [FBS], serum triglyceride [TG], cholesterol, low-density lipoprotein, high-density lipoprotein, insulin, testosterone, and dehydroepiandrosterone [DHEA]) were measured before and after therapy. Data were analyzed by Chi-square and McNemar's tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Significant decreases were seen after treatment with metformin in extent of hair loss (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008), wrist circle (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011), weight (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047), diastolic BP (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023), and DHEA (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.035). A significant decrease in TG was seen with pioglitazone treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047). In both groups, significant decreases in acne, menstrual disturbance, FBS, and serum insulin were seen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There is a significant amelioration of endocrine and metabolic indices with pioglitazone in PCOS patients. Although we were not able to recommend one treatment regime over the other, pioglitazone offers a useful, alternate treatment in women with PCOS who are not able to tolerate metformin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2230-8210.192925","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T03:57:33Z","timestamp":1477281453000},"page":"805-809","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":27,"title":["Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome"],"prefix":"10.4103","volume":"20","author":[{"given":"Karoon","family":"Shahebrahimi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Jalilian","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Bazgir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260327","doi-asserted-by":"crossref","first-page":"288","DOI":"10.12891\/ceog16222014","article-title":"Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer","volume":"41","author":"Hu","year":"2014","journal-title":"Clin Exp Obstet Gynecol"},{"key":"R2-20260327","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF03401302","article-title":"Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS)","volume":"12","author":"Valsamakis","year":"2013","journal-title":"Hormones (Athens)"},{"key":"R3-20260327","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2265.2008.03309.x","article-title":"Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome","volume":"70","author":"Cho","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/GCO.0b013e32833e1264","article-title":"Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: An update","volume":"22","author":"Katsiki","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R5-20260327","first-page":"16","article-title":"Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome","volume":"44","author":"Ziaee","year":"2012","journal-title":"Acta Med Indones"},{"key":"R6-20260327","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/09513590.2010.487589","article-title":"Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: Increasing efficacy and persistent safety over 30 months","volume":"26","author":"Ib\u00e1\u00f1ez","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"R7-20260327","doi-asserted-by":"crossref","first-page":"E841","DOI":"10.1210\/jc.2013-3918","article-title":"Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS","volume":"99","author":"Roe","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"e29052","DOI":"10.1371\/journal.pone.0029052","article-title":"Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy","volume":"6","author":"Vinaixa","year":"2011","journal-title":"PLoS One"},{"key":"R9-20260327","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1185\/03007995.2012.681636","article-title":"A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome","volume":"28","author":"Du","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2265.2010.03917.x","article-title":"Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: A meta-analysis","volume":"74","author":"Li","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R11-20260327","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijgo.2008.11.039","article-title":"Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome","volume":"105","author":"Haydardedeoglu","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1687-9856-2011-9","article-title":"of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. State of the art review: Emerging therapies: The use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS)","volume":"2011","author":"Geller","year":"2011","journal-title":"Int J Pediatr Endocrinol"},{"key":"R13-20260327","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mefs.2013.05.003","article-title":"Combined pioglitazone\u2013metformin and clomiphene citrate versus metformin and clomiphene citrate in induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome","volume":"19","author":"Abdel Fattah","year":"2014","journal-title":"Middle East Fertil Soc J"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/humrep\/deg264","article-title":"Selective effects of pioglitazone on insulin and androgen abnormalities in normo-and hyperinsulinaemic obese patients with polycystic ovary syndrome","volume":"18","author":"Romualdi","year":"2003","journal-title":"Hum Reprod"},{"key":"R15-20260327","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","article-title":"Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome","volume":"90","author":"Ortega-Gonz\u00e1lez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20260327","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.fertnstert.2010.06.058","article-title":"Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: A prospective randomized study","volume":"95","author":"Naka","year":"2011","journal-title":"Fertil Steril"},{"key":"R17-20260327","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"R18-20260327","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2011-3061","article-title":"Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): A multicenter, double-blind, placebo-controlled randomized trial","volume":"97","author":"Morin-Papunen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20260327","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0015-0282(16)58266-1","article-title":"Can metformin reduce insulin resistance in polycystic ovary syndrome?","volume":"65","author":"A\u00e7bay","year":"1996","journal-title":"Fertil Steril"},{"key":"R20-20260327","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20260327","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/humrep\/deg343","article-title":"Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin","volume":"18","author":"Glueck","year":"2003","journal-title":"Hum Reprod"},{"key":"R22-20260327","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-13-1035","article-title":"Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women","volume":"170","author":"Lerchbaum","year":"2014","journal-title":"Eur J Endocrinol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223308-201620060-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:26Z","timestamp":1786724786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223308-201620060-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/2230-8210.192925","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}